Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Applying UNIarray Platform for Biogen's MS Drug Research

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – German biotech firm Protagen today announced it will be using its UNIarray platform to support Biogen Idec's efforts in finding therapies for multiple sclerosis.

Under the terms of the agreement, the UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS. Protagen will also apply its expertise in autoantibody research to the alliance.

Financial and other terms of the deal were not disclosed.

"There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic levels," Peter Schulz-Knappe, CSO of Protagen, said in a statement. "Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.